In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Reckitt Boosts 2018 Guidance A Year After Gaining China Platform With MJN

This article is powered by The Rose Sheet

Executive Summary

Reckitt reports infant formula sales in China drove a 9% pro-forma increase in its child nutrition segment in second quarter, prompting a revenue forecast on the higher end of a 2%-3% projection. Firm says new infant formula and VMS products, including an improved Move Free formula, will continue to strengthen the sector.


Related Content

Infant Formula Production Stalls On Reckitt Benckiser's Latest Stumble
Perrigo ANDA Approval Brings New Options To Generic Mucinex DM Maximum Strength Portfolio
Reckitt At '2.0' On Nutrition Market Expansion But Question No. 1 Remains, Potential Pfizer Consumer Bid?
Nutritionals Mean Health Care To Reckitt And A Boon For China Business
Private Label Mucinex March Reaches Two Formulations


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts